# OnCo record prostate-high-risk (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/prostate-high-risk/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "prostate-high-risk" ;
  schema:name "Localised prostate cancer, high and very high risk"@en ;
  schema:alternateName "High-risk prostate cancer"@en, "Very high risk prostate cancer"@en, "Locally advanced prostate cancer"@en, "Grade Group 4 and 5 prostate cancer"@en, "Non-metastatic high-risk prostate cancer"@en ;
  schema:description "High-risk prostate cancer has Grade Group 4 or 5 disease, a PSA above 20 or a tumour growing beyond the gland. It is still curable, but needs radiotherapy with two to three years of hormone therapy, or surgery followed by radiotherapy, and adding abiraterone to hormone therapy now lengthens life in the highest-risk men."@en ;
  schema:url <https://onco.cc/cancers/prostate-high-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Prostate_cancer_staging> ;
  schema:citation <https://en.wikipedia.org/wiki/Prostate_cancer_staging>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/drugs/artera-ai-prostate/>, <https://onco.cc/drugs/decipher-prostate/>, <https://onco.cc/drugs/abiraterone/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/drugs/leuprolide/>, <https://onco.cc/drugs/degarelix/>, <https://onco.cc/drugs/relugolix/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/trials/hypo-rt-pc/>, <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/trials/stampede/>, <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/trials/propsma/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/terms/psa/>, <https://onco.cc/terms/biochemical-recurrence/> .